Showing results (401-410 of 450) with videos related to

Sort By:
Pageof 45
Cancer Research|August 2, 2017
FBW7 Loss Promotes Chromosomal Instability and Tumorigenesis via Cyclin E1/CDK2-Mediated Phosphorylation of CENP-AMamoru Takada, Weiguo Zhang, Aussie Suzuki, et al.
The American Journal of Surgical Pathology|April 14, 2009
Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibodyHerbert Haack, Laura A Johnson, Christopher J Fry, et al.
Blood Advances|August 8, 2022
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomesAiman J Faruqi, John A Ligon, Paul Borgman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2012
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignanciesRachel B Salit, Daniel H Fowler, Wyndham H Wilson, et al.
Blood Advances|January 4, 2018
Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathwaysSheryl M Gough, Liat Goldberg, Marbin Pineda, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 11, 2019
Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell CharacteristicsSandhya R Panch, Sandeep K Srivastava, Nasha Elavia, et al.
Life Science Alliance|November 21, 2018
CARM1 methylates MED12 to regulate its RNA-binding abilityDonghang Cheng, Vidyasiri Vemulapalli, Yue Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2021
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALLNirali N Shah, Daniel W Lee, Bonnie Yates, et al.
Blood Advances|October 7, 2021
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 daysLekha Mikkilineni, Bonnie Yates, Seth M Steinberg, et al.
Transplantation and Cellular Therapy|July 2, 2023
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell FailureElizabeth M Holland, Bonnie Yates, Seth M Steinberg, et al.
Pageof 45